Aegerion and its cholesterol drug will be biotech’s big thing in the coming week, says Adam Feuerstein, Sr. Columnist for TheStreet.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
























